InfraReDx's New LipiScan™ IVUS Coronary Imaging System to be Highlighted at TCT 2010
BURLINGTON, Mass., Sept. 17 /PRNewswire/ -- InfraReDx, Inc. , a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced that its new LipiScan™ IVUS Coronary Imaging System will be highlighted during the annual Transcatheter Cardiovascular Therapeutics meeting (TCT 2010 ). The novel device, which was recently cleared by the U.S. Food and Drug Administration (FDA), will be featured in scientific and clinical symposia, live case broadcasts, product demonstrations and poster abstract sessions. TCT 2010 is being held September 21-25, 2010 at the Walter E. Washington Convention Center ("the convention center") in Washington, D.C. TCT is the world's largest educational meeting specializing in interventional cardiovascular medicine and showcasing the latest advances in techniques, therapies and clinical research.
The Company expects to conduct a broad commercial launch of the system within the U.S. by year-end 2010, and anticipates regulatory approval and launch in Europe during 2011.
The LipiScan IVUS system utilizes a novel multimodality imaging catheter; the first ever to combine the complementary technologies of near-infrared (NIR) spectroscopy and intravascular ultrasound (IVUS). This combination enables interventional cardiologists to rapidly determine both the structure of plaque (via IVUS) along with its chemical composition (via NIR spectroscopy). NIR spectroscopy is the only technology cleared by the FDA for the specific task of detection of lipid-core coronary plaques (LCP). Such plaques can adversely impact the safety of stenting and are associated with heart attacks that occur in those who have received stents and in the general population.
Dr. James Muller, founder and chief executive officer of InfraReDx, Inc. noted that the "LipiScan IVUS system is the culmination of a major effort to develop